High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Balance Sheet: Strong Balance Sheet.
Past Returns: Outperforming stock! In past three years, the stock has provided 37.3% return compared to 9.3% by NIFTY 50.
Profitability: Recent profitability of 10% is a good sign.
Smart Money: Smart money has been increasing their position in the stock.
Size: It is among the top 200 market size companies of india.
Momentum: Stock price has a strong positive momentum. Stock is up 10.7% in last 30 days.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
No major cons observed.
Valuation | |
|---|---|
| Market Cap | 77.83 kCr |
| Price/Earnings (Trailing) | 22.32 |
| Price/Sales (Trailing) | 2.31 |
| EV/EBITDA | 10.9 |
| Price/Free Cashflow | 32.77 |
| MarketCap/EBT | 15.01 |
| Enterprise Value | 79.9 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 33.73 kCr |
| Rev. Growth (Yr) | 8.6% |
| Earnings (TTM) | 3.48 kCr |
| Earnings Growth (Yr) | 7.6% |
Profitability | |
|---|---|
| Operating Margin | 16% |
| EBT Margin | 15% |
| Return on Equity | 9.95% |
| Return on Assets | 6.63% |
| Free Cashflow Yield | 3.05% |
Growth & Returns | |
|---|---|
| Price Change 1W | 2.5% |
| Price Change 1M | 10.7% |
| Price Change 6M | 22.6% |
| Price Change 1Y | 18.2% |
| 3Y Cumulative Return | 37.3% |
| 5Y Cumulative Return | 8.7% |
| 7Y Cumulative Return | 8.2% |
| 10Y Cumulative Return | 6.3% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -1.88 kCr |
| Cash Flow from Operations (TTM) | 3.92 kCr |
| Cash Flow from Financing (TTM) | 119.78 Cr |
| Cash & Equivalents | 5.4 kCr |
| Free Cash Flow (TTM) | 1.96 kCr |
| Free Cash Flow/Share (TTM) | 33.69 |
Balance Sheet | |
|---|---|
| Total Assets | 52.55 kCr |
| Total Liabilities | 17.51 kCr |
| Shareholder Equity | 35.03 kCr |
| Current Assets | 28.65 kCr |
| Current Liabilities | 15.5 kCr |
| Net PPE | 13.28 kCr |
| Inventory | 11.19 kCr |
| Goodwill | 636.76 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.14 |
| Debt/Equity | 0.21 |
| Interest Coverage | 11.94 |
| Interest/Cashflow Ops | 9.84 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 4 |
| Dividend Yield | 0.35% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | -0.90% |
Balance Sheet: Strong Balance Sheet.
Past Returns: Outperforming stock! In past three years, the stock has provided 37.3% return compared to 9.3% by NIFTY 50.
Profitability: Recent profitability of 10% is a good sign.
Smart Money: Smart money has been increasing their position in the stock.
Size: It is among the top 200 market size companies of india.
Momentum: Stock price has a strong positive momentum. Stock is up 10.7% in last 30 days.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.35% |
| Dividend/Share (TTM) | 4 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 60.04 |
Financial Health | |
|---|---|
| Current Ratio | 1.85 |
| Debt/Equity | 0.21 |
Technical Indicators | |
|---|---|
| RSI (14d) | 67.39 |
| RSI (5d) | 80.07 |
| RSI (21d) | 73.73 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Sell |
| RSI21 Signal | Sell |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
Summary of Aurobindo Pharma's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
In the Q3 FY26 earnings call for Aurobindo Pharma, management provided an optimistic outlook highlighting their confidence in sustaining growth momentum across all segments. Key points include:
Revenue Growth: Management reported a consolidated revenue increase of 8.4% year-on-year to Rs.8,646 crores, driven by strong performance in European operations and stable U.S. business.
EBITDA Performance: EBITDA for the quarter reached Rs.1,773 crores with a margin of 20.5%, reflecting a 9% year-on-year growth, indicating robust operating leverage and execution of strategy.
European Market: The European business achieved a 27% year-on-year revenue growth, amounting to Rs.2,703 crores, with expectations to exceed Rs.1 billion in annual revenue by the end of FY26.
U.S. Market Prospects: U.S. revenue was reported at USD 420 million (excluding gRevlimid). A major transition is expected from the Dayton facility, predicted to significantly contribute to revenues starting FY27.
Production Capacity: Management plans to ramp up production capacity to over 10,000 metric tonnes annually over the next 12 months, with yield levels improving steadily.
Regulatory Developments: The introduction of a one-year CIF on minimum import price for Pen-G and related products is anticipated to create positive conditions for domestic manufacturing, enhancing cost competitiveness.
Future Initiatives: Management outlined plans for increasing focus on complex generics and biosimilars, emphasizing their commitment to building a robust pipeline through R&D investments amounting to Rs.409 crores (5% of total revenues).
Overall, management expects to achieve an internal EBITDA margin target of 20% to 21% for FY26, supported by a diversified operating model, expansion efforts, and strategic acquisitions. The outlook indicates readiness to respond to demand changes while maintaining operational rigor and capital allocation effectiveness.
1. Question: With respect to Eugia III inspection, what were the nature of observations, and will there be a temporary stoppage of production?
Answer: These are procedural observations. There is no stoppage of production required. We are confident in responding to the USFDA within 15 working days and believe there will be no issues.
2. Question: What kind of trajectory should we assume for U.S. injectable sales considering the Eugia inspection?
Answer: We're cautiously optimistic about this facility and expect the U.S. injectable sales to continue with double-digit growth next year, barring any further regulatory challenges.
3. Question: What is the current status of the Vizag injectable facility?
Answer: We filed for three products and have about ten more in the pipeline. Commercialization is expected to start in FY27, with significant contributions anticipated in FY28.
4. Question: Any updates regarding the Lannett acquisition and FTC approval?
Answer: We are confidently progressing with the FTC. We expect the transaction to complete in Q1 of FY27, with no negative surprises regarding portfolio overlap.
5. Question: What is the expected EBITDA impact from the Pen-G facility in FY26?
Answer: While we've improved yields and production, we expect significant contributions starting in Q1 FY27 as existing stock is consumed. EBITDA impact will depend on market conditions and MIP adjustments.
6. Question: What are the expectations regarding U.S. generics market sales and the OTC business for FY26?
Answer: The OTC segment is a fast-growing area, showing good momentum. We anticipate several new launches in FY27, consistent with our recent performance in nine new products.
7. Question: Could you clarify the Q3 gross margin performance and its sustainability?
Answer: Our gross margin stood at 59.7%, supported by improved performance from our Pen-G products. We anticipate sustaining improved margins, driven by better performance across all segments.
8. Question: What are the expected growth rates for your European business?
Answer: We expect our European business to ramp up significantly, especially with improved supplies from China, while already achieving low double-digit growth well above market rates.
9. Question: What are the company's key priorities regarding capital allocation moving forward?
Answer: Our main focus is on enhancing operational efficiency. We are not planning major greenfield projects but are open to strategic acquisitions if they fit our growth strategy.
10. Question: Can you give insights into your biosimilar strategy and milestones for the next year?
Answer: We aim to build on recent approvals with additional launches in Europe and growth markets, and we expect 2029 to be a significant inflection point for biotech development within our portfolio.
Understand Aurobindo Pharma ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI (JOINTLY HOLDING) | 33.5% |
| K NITYANANDA REDDY | 4.37% |
| KIRTHI REDDY KAMBAM | 3.45% |
| VENKATA RAMPRASAD REDDY PENAKA | 3.07% |
| AXIS CLINICALS LIMITED, TRIDENT CHEMPHAR LIMITED, RPR SONS ADVISORS PVT.LTD. (JOINTLY HOLDING) | 2.85% |
| M SIVAKUMARAN | 2.47% |
| NPS TRUST A/C - SBI PENSION FUND - UPS - CG SCHEM | 2.23% |
| KAMBAM SPOORTHI | 1.19% |
| K RAJESWARI | 0.31% |
| M SUMANTH KUMAR REDDY | 0.27% |
| TRIDENT CHEMPHAR LIMITED | 0.13% |
| AXIS CLINICALS LIMITED | 0.11% |
| PRASADA REDDY KAMBHAM | 0.05% |
| SUNEELA RANI PENAKA | 0.02% |
| PENAKA NEHA REDDY | 0% |
| K SURYAPRAKASH REDDY | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Aurobindo Pharma against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.14 LCr | 58.94 kCr | -1.50% | +1.60% | 37.93 | 7.03 | - | - |
| DIVISLAB | Divi's Lab | 1.57 LCr | 10.75 kCr | -7.80% | +6.40% | 63.26 | 14.58 | - | - |
| LUPIN | Lupin | 1.04 LCr | 26.49 kCr | -1.60% | +16.30% | 22.36 | 3.92 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.01 LCr | 36.09 kCr | -6.70% | +4.80% | 18.06 | 2.79 | - | - |
| CIPLA | Cipla | 96.9 kCr | 29.37 kCr | -11.20% | -16.90% | 21.31 | 3.3 | - | - |
Comprehensive comparison against sector averages
AUROPHARMA metrics compared to Pharmaceuticals
| Category | AUROPHARMA | Pharmaceuticals |
|---|---|---|
| PE | 22.32 | 33.31 |
| PS | 2.31 | 4.59 |
| Growth | 6.8 % | 8 % |
Aurobindo Pharma is a prominent pharmaceutical company based in Hyderabad, India, with the stock ticker AUROPHARMA.
With a market capitalization of Rs. 72,437.6 Crores, Aurobindo Pharma specializes in the manufacture of generic formulations and active pharmaceutical ingredients (APIs) across several global markets, including India, the USA, Europe, and Puerto Rico. The company provides a wide range of product formulations such as oral solids, liquids, injectables, and vaccines, alongside over-the-counter drugs.
In addition to its formulation offerings, Aurobindo Pharma develops APIs, biosimilars, biocatalysts, peptides, and hormones targeting various therapeutic areas such as the central nervous system, cardiovascular health, respiratory conditions, antibiotics, anti-retrovirals, anti-diabetics, gastroenterology, oncology, and dermatology. Notably, it produces antiretroviral drugs for those living with HIV and offers project-based chemistry contract services for drug lifecycle management, covering both sterile and non-sterile penicillins, cephalosporins, penems, and non-beta lactams.
The company has demonstrated strong financial performance, recording a trailing 12 months revenue of Rs. 31,571.6 Crores and a profit of Rs. 3,488.1 Crores over the past four quarters. Aurobindo Pharma has also shown significant growth, achieving 31.7% revenue growth over the past three years.
In terms of investor returns, Aurobindo Pharma distributes dividends, with a yield of 0.36% annually. In the last year, it purchased back 0.9% of its own stock, contributing positively to its share price. The company was incorporated in 1986 and remains committed to advancing pharmaceutical innovation and production.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
AUROPHARMA vs Pharmaceuticals (2021 - 2026)